|
|
 |
|
Viewing report
|
|
|
|
Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
GlobalData, Oct 2011, Pages: 78
Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global BPH market. The report identifies the key trends shaping and driving the global BPH market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global BPH sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData’s analysis suggests that the global benign prostatic hyperplasia (BPH) therapeutics market was worth $3.2 billion in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 6.4% for the next eight years to reach $5.2 billion by 2018. This growth rate is primarily attributed to the recent and impending patent expiry of Uroxatral and Avodart/Avolve in the US and the EU. However, the strong pipeline is set to offset the depleting revenues with the expected launch of Cialis and NX-1207 in the near future. The increase in the elderly population is expected to be a major driver of the BPH therapeutics market.
Scope
The report provides information on the key drivers and challenges of the BPH market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) BPH market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as phosphodiesterase-5 (PDE5) inhibitors, apoptosis inducers, estrogen receptor agonist and vasopressin agonist.
- Analysis of the current and future competition in the seven key countries BPH market. Key market players covered are Eli Lilly and Company, and Nymox Pharmaceutical.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the BPH therapeutics market.
- Analysis of key recent licensing and partnership agreements in BPH market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global BPH market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global BPH market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global BPH market landscape? – Identify, understand and capitalize.
Keywords
Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials
|
|
|
|
